Cellarity publishes groundbreaking framework for predicting drug safety in Nature Communications
SOMERVILLE, Mass., November 13, 2025 – Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the publication of a seminal manuscript in Nature Communications, which describes a novel framework for the prediction and characterization of drug-induced liver injury (DILI), along with open-source posting of the model and validation data.
DILI is one of the most significant safety challenges in developing therapeutics today, as hepatic safety events undetected in preclinical testing ...